

## Supplementary Materials

Supplementary Table 1. Distribution of patients with lung adenocarcinoma among TNM stages, chemotherapy and lobectomy.

| TNM1<br>Stage | Lung<br>lobectomy | No. of<br>patients | Chemotherapy |             | p-value <sup>2</sup> |
|---------------|-------------------|--------------------|--------------|-------------|----------------------|
|               |                   |                    | Yes          | No          |                      |
| Total         |                   | 306                | 154 (50.3%)  | 152 (49.7%) |                      |
| I-III         | Total             | 134                | 64 (47.8%)   | 70 (52.2%)  | 0.003                |
|               | Yes               | 83                 | 48 (57.8%)   | 35 (42.2%)  |                      |
|               | No                | 51                 | 16 (31.4%)   | 35 (68.6%)  |                      |
| IV            | Total             | 172                | 90 (52.3%)   | 82 (47.7%)  | 0.575                |
|               | Yes               | 5                  | 2 (40%)      | 3 (60%)     |                      |
|               | No                | 167                | 88 (52.7%)   | 79 (47.3%)  |                      |
| p-value       |                   |                    | < 0.001      |             |                      |

<sup>1</sup>TNM: tumor-node-metastasis; <sup>2</sup>Pearson Chi-square test

Supplementary Table 2. Treatment modality and survivals (months) of patients with lung adenocarcinoma in Henan, china.

| Lung<br>lobectomy | Chemotherapy | TMN1<br>Stage | No. of<br>patients | Survival months <sup>2</sup><br>(mean±Sd) | Min  | Max  |
|-------------------|--------------|---------------|--------------------|---|------|------|
| Yes               | Yes          | I-III         | 48                 | 27.1±18.3                                 | 3.6  | 83.8 |
| Yes               | Yes          | IV            | 2                  | 22.8±29.6                                 | 1.8  | 43.7 |
| Yes               | No           | I-III         | 35                 | 20.1±13.2                                 | 2.4  | 68.3 |
| Yes               | No           | IV            | 3                  | 16.5±7.2                                  | 10.1 | 24.3 |
| No                | Yes          | I-III         | 16                 | 16.5±10.6                                 | 1.3  | 38.9 |
| No                | Yes          | IV            | 88                 | 16.1±12.0                                 | 1.7  | 59.2 |
| No                | No           | I-III         | 35                 | 14.9±9.9                                  | 1.2  | 36.5 |
| No                | No           | IV            | 79                 | 10.5±12.0                                 | 0.1  | 77.9 |
| Total             |              |               | 306                | 16.8±14.0                                 | 0.1  | 83.8 |

<sup>1</sup>TNM: tumor-node-metastasis; <sup>2</sup>Significant difference in survival months among different treatment modalities (ANOVA test, P<0.001).